Story · Medicine & Biotech
Next-Generation Oral SERD Approved for Breast Cancer
1 outlet · first reported by MedPage Today on
(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated... (MedPage Today)
Coverage, in order
-
Next-Generation Oral SERD Approved for Breast Cancer(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.